NCT06435546Completed
Adherence to Oral Therapies in Advanced Breast and Prostate Cancers
Adherence to Oral Therapies in Advanced Breast and Prostate Cancers: a Pilot Study
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
AdOTAC is a pilot study, open, prospective, single-center, one-arm. The 200 patients will be included. Patient is included at Day 0. The included patient will have the opportunity to complete the self-questionnaires either at the ICL on Day 0, or at home up to 10 days after the date of inclusion in the study. Blood samples are collected the day of enrolment (Day 0) in order to measure the following biological markers: ferritin, serum iron, TSAT, albumin, and haemoglobin, except if performed as part of routine care in the previous 6 weeks.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 27 Nov 2023
- Start date
- 4 Jun 2024
- Primary completion date
- 12 Dec 2025
- Lead sponsor
- Institut de Cancérologie de Lorraine
- Diseases
- Prostate cancer
- NCT number
- NCT06435546
What you commit to
- Study type: Interventional
- Participants enrolled: 200
- From 4 Jun 2024 to the primary completion date, 12 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Undergoing intravenous or oral cytotoxic chemotherapy (capecitabine, cyclophosphamide, vinorelbine).
- Patient who has not yet started oral anticancer therapies or who has started for less than 3 months.
Other illness
- Patient with early breast cancer or localized prostate cancer.
Other
- Patient with life expectancy \< 3 months.
- Patient in progression
- Patient unable to read or speak French.
- Patient already included in another therapeutic trial with an experimental molecule.
- Persons deprived of their liberty or under guardianship (including curatorship).
Who the study is looking for
- Adult over 18 years old.
- Patient with inoperable advanced breast cancer treated with oral endocrine therapy and/or targeted therapy and patient with inoperable advanced prostate cancer treated with oral hormonal therapy and/or targeted therapy.
- Oral anticancer medications started for at least 3 months.
- With a performance status ≤ 3.
- Patient has understood, signed and dated the consent form.
- Patient covered by the social security system.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut de Cancérologie de Lorraine Coordinator of this site? Confirm its status | Vandœuvre-lès-Nancy | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.